The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008
To investigate the burden of ankylosing spondylitis in the Czech Republic as a baseline for future health economic evaluations. Data were obtained from two cross-sectional studies Beda I (2005) and Beda II (2008), performed in 1,008 and 509 patients, respectively. Methodology used was Cost-of-Illness prevalence-based analysis bottom-up approach. Analysis was performed from payer (health insurance companies) and societal perspective (including productivity costs using friction cost approach). Mean age of sample in Beda I and Beda II was 50.2 and 52.5 years, male were present by 61.0 and 62.7 %; average disease duration was 23.0 and 26.4 years, respectively. Mean total annual costs per patient in the sample were €4,782 in Beda I and €5806 in Beda II. Average direct costs per patient in the sample per year are estimated at €1,812 (Beda I) and €2,588 (Beda II) with the average productivity costs €2,970 (Beda I) and €3,218 (Beda II). We observed a small decrement in percentage (6.7 %) of productivity costs for Beda II as an influence of higher consumption of biologic drugs, hence higher direct costs and possible productivity preservation. The largest direct cost burdens were spa procedures (45.3 %, Beda I) and biological drugs (52.8 %, Beda II). Unique analysis of the burden of the AS in the Central-Eastern Europe presents health care resource and cost consumption by comparing two cross-sectional prevalence-based studies. Further analysis should be carried to obtain data connecting health status with costs consumption in order to analyse the AS from this perspective.
KeywordsHealth economics Ankylosing spondylitis Drug therapy Quality of health care Biologic agents
Authors would like to acknowledge Mr. Vedral from patient´s organisation for the cooperation and consultation during the manuscript writing. This work was supported by grant number 000 000 23728 – Ministry of Health of Czech Republic, by grant number SVV 265 005 - Charles University in Prague.
- 2.McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y et al (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 11:1–158Google Scholar
- 3.Boonen A, van der Linden SM (2006) The burden of ankylosing spondylitis. J Rheumatol 78(Suppl):4–11Google Scholar
- 6.Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H (2006) Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002–2003. Clin Exp Rheum 24(5):499–507Google Scholar
- 9.Pavelka K, Stolfa J, Vencovsky J (2004) Supplement of standard protocol for treatment ofankylosing spondylitis. Ces Revmatol 1:30–035 CzechGoogle Scholar
- 13.Sleglova O, Dusek J, Olejarova M, Hornatova H, Draska L, Vencovsky J (2004) Evaluation of status and quality of life in patients with ankylosing spondylitis––validation of Czech versions of bath questionnaires––BAS-G, BADAI and BASFI. Ces Revmatol 2:43–54 CzechGoogle Scholar
- 17.[Price list of VZP, version 650. Health Insurance Companies]. http://www.vzp.cz/poskytovatele/ciselniky/hromadne-vyrabene-lecive-pripravky-a-potraviny-pro-zvlastni-lekarske-ucely#archiv (accessed 19 September 2011) [Czech]
- 20.[Central bank exchange rate fixing –averages]. http://www.cnb.cz/en/financial_markets/foreign_exchange_market/exchange_rate_fixing/currency_average.jsp?code=EUR (accessed 5 June 2011) [Czech]